Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling
Executive Summary
Only 14 of the 170 brand-generic patent suit settlements in US during FY 2015 potentially involve payments to delay generics; number drops to 5 when payments for litigation fees are excluded.
You may also be interested in...
Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?
AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.
Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?
AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.